NLS Pharmaceutics and Kadimastem Merger Approved
Ticker: NCEL · Form: 6-K · Filed: Jan 31, 2025 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Jan 31, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: merger, acquisition, corporate-event
Related Tickers: NLS
TL;DR
NLS Pharmaceutics merger with Kadimastem gets shareholder green light.
AI Summary
On January 31, 2025, NLS Pharmaceutics Ltd. announced that Kadimastem shareholders approved the merger with NLS Pharmaceutics. This filing incorporates the press release detailing this significant corporate event.
Why It Matters
The approval of the merger between NLS Pharmaceutics and Kadimastem is a key step towards consolidating their operations and potentially advancing their drug development pipelines.
Risk Assessment
Risk Level: medium — Merger approvals are significant events, but the actual integration and success of the combined entity carry inherent risks.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant and acquiring company
- Kadimastem (company) — Company being merged
- January 31, 2025 (date) — Date of the press release and shareholder approval
FAQ
What was the main event reported in the Form 6-K filed on January 31, 2025?
The main event reported was the approval by Kadimastem shareholders of the merger with NLS Pharmaceutics.
Which company issued the press release that is part of this filing?
NLS Pharmaceutics Ltd. issued the press release.
What is the Commission file number for NLS Pharmaceutics Ltd.?
The Commission file number is 001-39957.
What is the address of NLS Pharmaceutics Ltd.'s principal executive offices?
The address is The Circle 6, 8058 Zurich, Switzerland.
Which SEC registration statements does this Form 6-K filing get incorporated into?
This Form 6-K is incorporated into NLS Pharmaceutics Ltd.'s Registration Statements on Form F-3, specifically File Nos. 333-282788, 333-262489, 333-268690, and 333-269220.
Filing Stats: 258 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2025-01-31 07:47:42
Filing Documents
- ea0229241-6k_nlsphar.htm (6-K) — 11KB
- ea022924101ex99-1_nlsphar.htm (EX-99.1) — 18KB
- 0001213900-25-008561.txt ( ) — 30KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: January 31, 2025 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2